Author: KinaseInhibitorLibrary

While topical administration is effective in the treatment of anterior chamber diseases, it is ineffective in the treatment of diseases afflicting the posterior segments of the eye. Major problems include washing away of the drug by tears and the inefficient diffusion of drug from the corneal side to the posterior. Systemic injection does deliver drugs to the posterior of the eye but is also associated with non-specific accumulation of drug in other organs. In addition the blood retinal barrier also hinders the diffusion of drug into the posterior chamber. In light of this information, intraocular drug injections have gained in importance. However, although they achieve therapeutic drug levels, they are associated with high vitreal clearance which necessitates multiple injections. Many therapeutic strategies have been developed in recent years. One such method is the use of biomaterial drug delivery devices either in the form of implants or as micro or nanoparticles. Despite of their ability to release therapeutic agents for a prolonged period of time, ocular rod implants have been found to be responsible for causing retinal detachment and endophthalmitis. With the expansion of nanotechnology in medicine, a wide variety of nanoparticle drug releasing devices have been fabricated and tested for their ability to treat a wide range of diseases. Many studies have been done to explore the possibility of using polymeric micro and EX 527 nanoparticles for anterior and posterior chamber drug delivery. Although microparticles have better drug loading capacity than nanoparticles, the latter is recognized as favorable drug carrier due to its low risk on hampering normal vision. Although different types of nanoparticles have been investigated for their ability to target different cells, tissues and to cure different ocular diseases. very limited studies have been done to systematically evaluate the effect of material physical and chemical properties on their ocular tissue and cell compatibility. It is well established that the physical and chemical properties of materials affect their cell and tissue compatibility. We thus assumed that nanoparticles made of different materials are likely to cause different extents of acute tissue responses in the eye. To test this hypothesis, nanoparticles made of different materials were included in this study. Specifically, nanoparticles were made out of degradable polymers like poly, hydrogels like poly N-isopropyl acrylamide, non-degradable materials like polystyrene, and biological materials like hyaluronic acid. The ocular compatibility of these nanoparticles was evaluated using rabbit intravitreous implantation model. After implantation for different periods of time, we measured the changes in intraocular pressure. At the end of the studies, animals were sacrificed and ocular tissues were histologically evaluated. The effect of material properties on the ocular tissue responses was then determined to show that it can play a key role in determining the fate of nanoparticles in the eye. Drug delivery to the back of the eye, especially the posterior segments, is a key research area and important considering numerous ocular diseases that afflict that region.

This review cannot conclude which factors are more influential, and future studies are needed to uncover the reasons why some QIs have low pass rates. On the other hand, medication management and use, hearing loss and continuity of care, MK-1775 scored markedly higher than other conditions regardless of the setting and patient population and regardless of which QIs were used to assess them. This could be due to the increased attention to medication management in general, or partly attributable to chance due to the relatively low number of studies including these conditions. Although based on only one study, quality of care for falls in the hospital setting scored markedly higher than in other settings. This difference may be explained by fewer QIs being used in the hospital study and differences in the QIs that were used in the individual studies, or by increased attention to falls in hospitals and the more intensive care given to hospitalized patients compared to other settings. There was only one UK study in the primary care setting compared to three US studies. Although different QIs were used, the care for ischemic heart disease, diabetes, depression, hypertension, osteoporosis, urinary incontinence, stroke and vision care had better quality in the UK primary care setting compared to the US. It is plausible that this is due to differences in diagnoses and treatment of these conditions between the countries, or a different prevention program. This finding does not warrant general conclusions about the differences in quality of care between the countries, and more studies are needed. Although comparison of scores per setting was based on limited studies and QIs, it may reveal the need for extra attention to the conditions that form good candidates for quality improvement. These are the conditions that had mean scores below 50%. In managed care settings these conditions are: osteoarthritis, depression, urinary incontinence, falls, dementia, end-of life care, malnutrition, pressure ulcer care, and pneumonia care. In nursing homes, dementia, depression, diabetes, falls, stroke, ischemic heart disease, heart failure, osteoarthritis, osteoporosis, atrial fibrillation, vision and hypertension had consistently low scores. Finally, in primary care, dementia, UI, falls, osteoarthritis and vision care show room for improvement. According to the ACOVE indicators and the studies identified by our review, it appears that the quality of care for the elderly is low. However, we can only draw limited conclusions from these studies, for several reasons. First, although the QIs are generally evidence–based and have been developed in multiple Delphi rounds using expert panels, it is still possible that individual physicians will debate the content of specific QIs. Although the QIs are conjectured to represent minimal care, it is possible that low pass rates may represent legitimate differences of medical opinion. Second, undocumented patient refusal of the offered care could lead to a lower measured pass rate. Various studies, however, have taken this aspect into account and counted an indicator as passed when a patient refused the indicated care or when a contraindication existed.

RV insertion points and anterolateral wall of the left ventricle. Importantly, prognosis and cardiac function are poorer in DMD patients who have late gadolinium enhancement. In the mdx mouse, standard measures of left ventricular function, including ejection fraction, end systolic volume and wall thickening, do not become abnormal until 9 to 11 months of age. However, MRI has identified early abnormalities in cardiac wall strain and torsion, as well as right ventricular dysfunction at 6–8 months. Imaging studies of cardiac function in the mdx mouse have focused on mice at one specific age, or imaged different groups of mice at different ages, the earliest time point being,5- months. Here we serially imaged the same group of male mdx mice and littermate male wild type controls using MRI at 1 month after birth and at four further timepoints up to 1 year. We assessed left and right ventricular systolic function, diastolic function and response to dobutamine stress. Further, we report the first use of late gadolinium enhancement to identify regions of myocardial fibrosis in mdx mice. In vivo measures of fibrosis correlated with cardiac function, and may offer a sensitive and clinically relevant in vivo method for assessing the efficacy of experimental treatments for muscular dystrophy. In vivo MRI of mouse models of human cardiac disease can give valuable insights into pathology and therapy. Although the mdx mouse model of muscular dystrophy has been studied using ultrasound and haemodynamic measurements, there are limited data from MRI studies and no reports of serial MR imaging of disease progression in the same mdx mice over time. Clinically and experimentally, cardiac MRI is more sensitive to small alterations in cardiac function than other imaging modalities, including ultrasound. Hence, we anticipated that the application of MRI to the mdx mouse, known to have only mild cardiomyopathy when young, may identify subtle changes previously missed by other techniques. In agreement with previous reports, standard cine-MRI did not show altered resting LV function in mdx mice until 9 months of age. However, high temporal resolution cine-MRI indicated that peak LV filling and ejection rates were lower at 3 and 6 months of age, suggesting impaired systolic and diastolic function even in young animals, as has been observed ex vivo in isolated, Nutlin-3 working 3-month-old mdx mouse hearts and in vivo in 8-month-old mice. Interestingly, differences in LV filling and ejection rates were not detected at 12 months, suggesting that progressive remodeling and hypertrophy may compensate for dysfunction and mask the original abnormalities at later time points. This is supported by the study of Li et al, which reported increased regional strain and torsion in the 2-month-old mdx mouse heart and reduced torsion by 10 months. All mice used in this study were male; female mice may have given different results. We have reported RV dysfunction in mdx mice at 8 months that precedes LV dysfunction, probably owing to pulmonary hypertension and dysfunction of the diaphragm muscle. Here, by performing serial imaging, we were able to determine that resting RV function was unaltered at 1 month, but abnormal as early as three months, with RV-ESV increased and RV-EF reduced.

Iterative expert panel meetings with review of the relevant evidence were used to generate a set of indicators to assess the quality of the process of care, rather than outcomes. RAND researchers postulate that these QIs represent minimal care rather than optimal care for the vulnerable elderly population, and are meant to assess and ultimately improve the quality of care. The resulting set consists of explicitly phrased IF-THEN clinical rules with comprehensive coverage of general medical and geriatric conditions, including comorbidities. These rules are intended to evaluate, by means of gauging adherence to the rules, the extent to which the care being delivered meets minimal standards of quality. The following is an example of an ACOVE indicator : “IF a vulnerable elder reports a history of two or more falls in the previous year, THEN there should be documentation of a basic fall history within three months of the report. ACOVE-1 represents the first original set of QIs. The second phase of ACOVE aimed at evaluating various interventions in primary care practices in order to improve care, but the QI set was not changed. The ACOVE-3 QI set is an updated and expanded set of QIs including five new conditions: COPD, colorectal cancer, breast cancer, sleep disorders, and benign prostatic hypertrophy. Because ACOVE QIs or adaptations thereof have been used for over a decade for the assessment of quality of care. This paper reviews the PR-171 studies that assessed the quality of care for elderly patients using ACOVE QIs in order to evaluate the state of the quality of care for the reported conditions. In this systematic review we described the results of 17 research papers using the ACOVE quality indicators to assess the quality of care. The assessment of care was performed in a variety of care settings, in several different elderly patient populations and for multiple conditions. Due to this heterogeneity and the fact that the studies used different subsets of the ACOVE QIs or adaptations thereof, the results of the studies cannot be directly compared and hence a quantitative meta-analysis is not justified. However, considering that many studies assessed the quality of care for multiple conditions simultaneously and 50% of the QIs had a pass rate below 50%; some general conclusions can be drawn about areas to which improvement initiatives should be focused. An overall conclusion is that there is much room for care improvement for the elderly population. Individual studies have already shown the need for greater focus on elderly care. This finding is supported by our review. Based on the included studies the overall quality scores for dementia, depression, osteoporosis and osteoarthritis were notably low. In addition to the conditions above, hypertension, ischemic heart disease, pressure ulcer, pain management, falls and urinary incontinence scored below 50% at the QI level. In the interest of maintaining a good quality of life for elderly patients it is very important to treat geriatric conditions, and it may even be unethical to ignore this need. Although care for many conditions showed deficiencies, geriatric conditions like dementia and falls seem to show greater deficiencies than others.

Administration of drug directly into the vitreous is also associated with a lot of problems; clearance of the drug being one of the main drawbacks. In light of this fact, nanotechnology has come to the forefront of ocular drug delivery and as such, understanding ocular tissue response to implanted nano-biomaterials is of paramount significance. Our selection of materials to synthesize various nanoparticles was based on the SP600125 following facts. First, a vast majority of drug releasing nanodevices are made out of FDA approved polymers like PLLA and PLGA and are usually in the range of 10 nm to 1000 nm. In fact, previous studies have shown that particles in the range of 20 nm to 200 nm have the highest affinity to tissue. Second, hydrogels like PNIPAM have been extensively researched for drug delivery applications. Thirdly, HA is a major component of the vitreous and as such, their presence in the eye should be tolerable. HA makes up a sizeable proportion in the retinal pigment epithelium and interphotoreceptor matrix. Considering this information, we selected nanoparticles made out of PLLA, PS, HA and PNIPAM in the size range of 100 to 200 nm. It is well established that material properties trigger different extent of soft tissue responses. We thus assumed that material properties would exert some influence on ocular tissue reactions. Very few studies have been done to assess the effect of material properties on ocular compatibility of particles. Nevertheless, studies have found that PLLA and PLGA nanoparticles can be used for delivery of high molecular weight drugs to the retina, and poly is well tolerated by retinal tissue for at least 4 weeks. Non-toxic chitosan and hyaluronic acid have been found to be good drug carriers, and carbodiimide crosslinked hyaluronic acid has been shown to have good ocular compatibility in the anterior chamber. PNIPAM hydrogel grafted with chitosan has also been applied as a thermally responsive ophthalmic drug delivery device. Also most of the studies until now have mainly focused on visual signs of inflammation to suggest lack of biocompatibility. To determine the ocular tissue responses to particle implants, we first measured the IOP changes following intravitreous implantation of particle. The fluctuation of IOP indicates the balance between production and drainage of aqueous humor and hence it was measured to determine the impact of various nanoparticle injections on aqueous humor drainage. In addition, it has been documented that ocular inflammation strongly influences the IOP. Diseases like glaucoma have been shown to increase IOP while inflammatory conditions produced by anterior uveitis and iritis were found to reduce IOP. Substantial studies in glaucoma research have focused on using various pharmacological approaches to reduce IOP for prolonged period of time. Interestingly, our studies have found that the intravitreous implantation of particles prompted different extent of IOP reduction. Specifically, we found that PNIPAM and PS particles triggered the maximum reduction in IOP, while PLLA particles caused a rather mild reduction in IOP. Most interestingly, our results show that the implantation of HA particles trigger minimal or no IOP reduction.